Baesi Kazem, Velayati Ali Akbar, Ashtiani Masoumeh Farrokh, Fakhredini Kamal, Banifazl Mohammad, Larijani Mona Sadat, Basimi Parya, Ramezani Amitis
Hepatitis & AIDS Dept., Pasteur Institute of Iran, Tehran, Iran.
Masih Daneshvari Hospital, Shahid Beheshti University of Medical Science, Tehran, Iran.
Curr HIV Res. 2021;19(5):391-397. doi: 10.2174/1566523221666210707142838.
Hepatitis C virus (HCV) acts in the host as a complicated mixture of related variants with the potency to genetically escape host immune responses. Direct acting antivirals (DAAs) have been approved for HCV treatment with shorter duration, better cure rates and lower side effects. However, naturally occurring resistance associated substitutions (RASs) create some obstacles to this antiviral therapy success.
In this study, we aimed at the determination of the naturally occurring NS3/4A RASs in HCV/human immunodeficiency virus (HIV)infected patients.
A total of 120 DAA-naïve HCV-HIV co-infected patients were included. HCV NS3/4Agenome region was amplified with PCR and mutation analysis was performed by Sanger sequencing technique. The amino acid sequence diversity of the region was analyzed using geno2pheno HCV.
Phylogenetic analysis showed that 73 cases were infected by 3a and 47 subjects by subtype1a. The overall RASs among studied subjects were observed in 6 (5%) individuals from 120 studied cases who were infected with HCV 1a. V36M/L, Q80L, S122G/L, R155T/G, A156S, D168Y/N and S174A/N/T mutations were detected in this study.
Although the prevalence of RASs was totally low in this study, the presence of several cases of double and triple mutants among this population suggests prior evaluation of protease inhibitors related mutations before initiation of standard treatment and also an investigation on a large population could be of high value.
丙型肝炎病毒(HCV)在宿主体内以相关变体的复杂混合物形式存在,具有在基因上逃避宿主免疫反应的能力。直接抗病毒药物(DAAs)已被批准用于HCV治疗,疗程更短、治愈率更高且副作用更低。然而,天然存在的耐药相关替代(RASs)给这种抗病毒治疗的成功带来了一些障碍。
在本研究中,我们旨在确定HCV/人类免疫缺陷病毒(HIV)合并感染患者中天然存在的NS3/4A RASs。
共纳入120例未接受过DAAs治疗的HCV-HIV合并感染患者。用PCR扩增HCV NS3/4A基因组区域,并通过桑格测序技术进行突变分析。使用geno2pheno HCV分析该区域的氨基酸序列多样性。
系统发育分析显示,73例患者感染3a型,47例患者感染1a亚型。在120例研究病例中,有6例(5%)感染HCV 1a的个体出现了总体RASs。本研究检测到V36M/L、Q80L、S122G/L、R155T/G、A156S、D168Y/N和S174A/N/T突变。
尽管本研究中RASs的总体患病率较低,但该人群中存在几例双突变和三突变病例,这表明在开始标准治疗前应先评估蛋白酶抑制剂相关突变,并且对大量人群进行调查可能具有很高的价值。